Did you mean amitifadine of en 10 of dov 21,947 of アミティファジン?
Displaying drugs 601 - 625 of 8823 in total
Drotaverine
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... [A231614] More recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia ... Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal …
Daptomycin
Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked...
Approved
Investigational
Matched Description: … Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive …
Aluminum hydroxide
Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
Approved
Investigational
Matched Description: … Subsequent increases in pH may inhibit the action of pepsin. …
Matched Mixtures name: … แอนตาซิล พลัส 100 ... แอนตาซิล พลัส 100 ... DICLOFENACO SÓDICO 100 MG - HIDROXIDO DE ALUMINIO GEL EQUIVALENTE A200 MG …
Matched Mixtures name: … แอนตาซิล พลัส 100 ... แอนตาซิล พลัส 100 ... DICLOFENACO SÓDICO 100 MG - HIDROXIDO DE ALUMINIO GEL EQUIVALENTE A200 MG …
Zalcitabine
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is...
Approved
Investigational
Matched Description: … elongation of DNA chains, thus resulting in the termination of viral DNA growth. ... of viral DNA by binding to reverse transcriptase. ... This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the …
Nonacog beta pegol
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Ferric maltol
Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Colchicine
Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events....
Approved
Matched Description: … prevention of major cardiovascular events. ... [L8192] Colchicine is used in the treatment of gout flares and Familial Mediterranean fever,[L8138] and …
Meclofenamic acid
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Approved
Vet approved
Pegunigalsidase alfa
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … allowing it to reach target organs with a lower dose and frequency of administration. ... Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term ... [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and …
Cisatracurium
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... [A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release. ... Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available …
Clonazepam
A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796]
Since being...
Approved
Illicit
Matched Description: … of gamma-aminobutyric acid receptor responses. ... [FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement ... Now available as a generic medication, the agent continues to see exceptionally high use as millions of …
Strontium chloride
Strontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. This kind of barrier protection for tooth hypersensitivity has, however, been...
Approved
Matched Description: … Strontium chloride (SrCl2) is a salt of strontium and chloride. ... chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of ... This kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste …
Testolactone
An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Approved
Investigational
Matched Description: … An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer …
Fidaxomicin
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is...
Approved
Matched Description: … of fidaxomicin. ... diarrhea in adult patients over the age of 18. ... patients over the age of 6 months in the treatment population. …
Alfuzosin
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Description: … 80%-90% of those over 70. ... Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads ... The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to …
Human vaccinia virus immune globulin
Human vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine who possess high titers of anti-vaccinia virus antibody [FDA Label, A33814]. The IgG fraction is purified by the anion-exchange column chromatography...
Approved
Matched Description: … from healthy donors previously vaccinated with live vaccinia virus vaccine who possess high titers of ... vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of ... Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human …
Troglitazone
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. …
Relugolix
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … treatment of prostate cancer. ... [L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. ... Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several …
Flutamide
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast ... [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... [A254387]
The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Estradiol acetate
Estradiol acetate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. ... Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. ... Administration of synthetic and bioidentical forms of estrogen, such as estradiol acetate, has shown …
Zilucoplan
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of...
Approved
Matched Description: … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein ... [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized …
Olopatadine
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of doxepin, which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and...
Approved
Matched Description: … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of ... It is a structural analog of [doxepin], which has a minimal anti-allergic activity. ... [L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes …
Trofinetide
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE ... [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. ... [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[ …
Displaying drugs 601 - 625 of 8823 in total